9.19
price down icon4.67%   -0.45
after-market After Hours: 9.64 0.45 +4.90%
loading
Alvotech stock is traded at $9.19, with a volume of 168.91K. It is down -4.67% in the last 24 hours and down -19.10% over the past month. Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$9.64
Open:
$9.46
24h Volume:
168.91K
Relative Volume:
1.13
Market Cap:
$2.77B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-4.9676
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
-20.43%
1M Performance:
-19.10%
6M Performance:
-25.28%
1Y Performance:
-19.39%
1-Day Range:
Value
$9.15
$9.49
1-Week Range:
Value
$9.15
$11.47
52-Week Range:
Value
$9.15
$14.76

Alvotech Stock (ALVO) Company Profile

Name
Name
Alvotech
Name
Phone
-
Name
Address
-
Name
Employee
999
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
ALVO's Discussions on Twitter

Compare ALVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ALVO
Alvotech
9.19 2.77B 391.87M -441.45M -301.21M -1.85
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
163.50 72.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.98 47.08B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.16 45.99B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.29 17.52B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
312.26 13.78B 2.76B 1.11B 898.10M 22.77

Alvotech Stock (ALVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Initiated UBS Buy
Jan-29-24 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Upgrade Citigroup Sell → Neutral
Sep-21-23 Initiated Barclays Equal Weight
Sep-07-22 Initiated Morgan Stanley Equal-Weight
Sep-06-22 Downgrade Citigroup Buy → Sell
Jul-26-22 Initiated Citigroup Buy
View All

Alvotech Stock (ALVO) Latest News

pulisher
Apr 01, 2025

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com

Apr 01, 2025
pulisher
Mar 31, 2025

Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®

Mar 31, 2025
pulisher
Mar 31, 2025

Oaktree Capital Management LP Sells 606,322 Shares of Alvotech (NASDAQ:ALVO) - MarketBeat

Mar 31, 2025
pulisher
Mar 30, 2025

Alvotech (NASDAQ:ALVO) Issues Earnings Results - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Alvotech (NASDAQ:ALVO) Stock Price Down 7.6%Time to Sell? - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance

Mar 30, 2025
pulisher
Mar 29, 2025

Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia

Mar 29, 2025
pulisher
Mar 28, 2025

Aurion names Arnaud Lacoste CEO - BioCentury

Mar 28, 2025
pulisher
Mar 28, 2025

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com

Mar 28, 2025
pulisher
Mar 28, 2025

Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Mar 28, 2025
pulisher
Mar 28, 2025

Alvotech Achieves Record Revenue Growth in 2024 - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg.com

Mar 27, 2025
pulisher
Mar 27, 2025

Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times

Mar 27, 2025
pulisher
Mar 26, 2025

Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech : Press Release Full Year 2024 - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech Shatters Growth Records: 427% Revenue Surge Signals Major Biosimilar Breakthrough - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech SA MHRA Accepts Marketing Application For AVT23 Biosimilar To Xolair - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

UK Medicines and Healthcare Products Regulatory - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Earnings Scheduled For March 26, 2025 - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

UK Medicines and Healthcare Products Regulatory Agency - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewswire Inc.

Mar 26, 2025
pulisher
Mar 25, 2025

Royce & Associates LP Raises Stock Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Alvotech, Partners Say UK Regulator Accepted Market Application for Proposed Xolair Biosimilar - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN

Mar 24, 2025
pulisher
Mar 23, 2025

Alvotech (ALVO) Expected to Announce Earnings on Wednesday - MarketBeat

Mar 23, 2025
pulisher
Mar 23, 2025

Short Interest in Alvotech (NASDAQ:ALVO) Expands By 21.7% - MarketBeat

Mar 23, 2025
pulisher
Mar 21, 2025

Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003 - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars - Drug Store News

Mar 21, 2025
pulisher
Mar 20, 2025

Northland reiterates Alvotech stock with $28 target on acquisition By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Alvotech Acquires Xbrane's R&D Operations, Expanding Biosimilars Development Capabilities - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Northland reiterates Alvotech stock with $28 target on acquisition - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Icelandic Biotech Company Alvotech to Explore Listing in Stockholm - MarketWatch

Mar 20, 2025
pulisher
Mar 20, 2025

Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03 - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Alvotech Snaps Up Xbrane’s R&D And Cimzia Rival For $27m - insights.citeline.com

Mar 20, 2025
pulisher
Mar 20, 2025

Alvotech Expands with Acquisition of Xbrane’s R&D Operations - TipRanks

Mar 20, 2025

Alvotech Stock (ALVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$10.77
price up icon 4.06%
$32.65
price up icon 0.37%
$97.42
price down icon 0.52%
$8.66
price up icon 0.70%
$108.31
price up icon 1.22%
$312.26
price up icon 1.75%
Cap:     |  Volume (24h):